Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia
- 17 January 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 54 (4) , 290-298
- https://doi.org/10.1002/pros.10196
Abstract
Prostatic adenocarcinoma is the most common malignancy among men in the western world but the diagnostic and prognostic criteria for it are still not clearly defined. Additional means for its diagnosis and prognosis are clearly needed. Previously it has been shown that cystatin A is expressed in the basal cells of normal prostate and the expression disappears in prostatic carcinoma. We have now studied the expression of both cystatins A and B in benign prostatic hyperplasias (BPH), prostatic intraepithelial neoplasias (PIN) and carcinomas of the prostatic epithelium and compared it with the expression of high molecular weight (HMW) cytokeratin as well as the proliferation markers cyclin A and Ki-67. The expression of the proteins was immunohistochemically assessed using 33 total prostatectomy specimens. Cystatin A was expressed in the basal cells in all cases of BPH, low-grade PIN, and high-grade PIN whereas carcinomas showed no staining of cystatin A. The 34βE12 cytokeratin expression was similar to basal cystatin A staining and was not seen in carcinoma foci. Cystatin B showed both nuclear and cytoplasmic expression in the columnar epithelial cells. The decrease in median cytoplasmic staining of cystatin B in carcinomas compared to other lesions was significant, but there was a significant increase in expression with dedifferentiation of carcinoma. Also cyclin A and Ki-67 staining were significantly different in non-carcinomatous foci compared to carcinoma foci and had a remarkably similar negative correlations with basal cystatin A and 34βE12 staining. The results show that cystatin expression can be used as an aid in the diagnosis of prostatic adenocarcinoma and especially cystatin A in the distinction between high grade PIN and grade I carcinoma. Prostate 54: 290–298, 2003.Keywords
Funding Information
- Arvo and Inkeri Suominen Foundation, Salo; Finland
This publication has 25 references indexed in Scilit:
- Recent advances in the histopathology and molecular biology of prostate cancer.BJU International, 2000
- Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survivalThe Prostate, 1999
- Mutations in the Gene Encoding Cystatin B in Progressive Myoclonus Epilepsy (EPM1)Science, 1996
- Expression of acid cysteine proteinase inhibitor (acpi) in the normal human prostate, benign prostatic hyperplasia and adenocarcinomaInternational Journal of Cancer, 1995
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993
- Application of the Monoclonal Antibody Ki-67 on Prostate Biopsies to Assess the Proliferative Cell Fraction of Human Prostatic CarcinomaJournal of Urology, 1991
- Amino acid sequence of the intracellular cysteine proteinase inhibitor cystatin B from human liverBiochemical and Biophysical Research Communications, 1985
- Immunolocalization of human cystatins in neutrophils and lymphocytesHistochemistry and Cell Biology, 1984
- Epidermal SH-Protease Inhibitor in Human Neoplasms and their MetastasesPathology - Research and Practice, 1980
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974